Related Articles
High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy
Efficacy and safety of PD‑1/PD‑L1 inhibitors combined <br />with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis
Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials
Plasma vascular endothelial growth factor 165 in advanced non‑small cell lung cancer